Gan & Lee Pharmaceuticals.

This study tests a new drug called GZR18 against the approved weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. The study is open-label, meaning both partic…

This study tests whether a weight loss injection called GZR18 can be given less often (every 4 weeks) and still work safely. It includes 500 adults who are overweight or obese and have already completed a year of treatment with the same drug. Participants will receive the shot ev…

This study tests a new insulin drug, GZR4, against another insulin (Insulin Icodec) in 300 adults with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and causes fewer side effects like low blood sugar. Participants may also…

This study tests a single dose of GZR18 injection in 32 adults with obesity or overweight, comparing those with normal kidneys to those with mild, moderate, or severe kidney problems. The goal is to see how kidney function affects drug levels and safety. Results will help doctors…

This early-stage study is testing an experimental injection called GZR18 in 60 overweight or obese adults. The main goals are to see how the drug affects stomach emptying and whether it changes how the body processes three common medications: digoxin, rosuvastatin, and warfarin. …

This study checks if a new version of the experimental drug GZR18 works the same as the old version in 138 healthy adult men. Participants get one injection and are monitored for 35 days with blood tests. The goal is to see if the drug levels in the body are similar, not to treat…